Firefly Neuroscience (AIFF) Return on Sales (2010 - 2026)

Firefly Neuroscience's Return on Sales history runs 16 years deep, the most recent figure standing at 0.04% for Q1 2026.

• On a quarterly basis, Return on Sales rose 297.0% year-over-year to 0.04% in Q1 2026; TTM through Mar 2026 was 0.03%, a 146.0% increase from a year earlier, with the FY2025 full-year figure at 0.14%, up 83.0% from the prior year.
• Return on Sales fell to 0.04% in Q1 2026 per AIFF's latest filing, from 0.04% in the prior quarter.
• Across five years, Return on Sales topped out at 0.04% in Q4 2025 and bottomed at 3.01% in Q1 2025.
• The 5-year median for Return on Sales is 0.01% (2022), against an average of 0.32%.
• Across the five-year window, Return on Sales sank 120 bps in 2024 and soared 297 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.04% in 2022, then soared by 101 bps to 0.0% in 2023, then sank by 449868 bps to 1.21% in 2024, then jumped by 103 bps to 0.04% in 2025, then slumped by 200 bps to 0.04% in 2026.
• Per Business Quant, the three latest AIFF Return on Sales figures stand at 0.04% (Q1 2026), 0.04% (Q4 2025), and 0.07% (Q3 2025).